Subscribe

News
Media
Conferences
Publications
Events
CE
Resources
Subscribe

Spotlight -

Community/Retail|

Pharmacy Technician|

Opinion|Videos|May 14, 2024

Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Author(s)Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP, Kate Cabral, PharmD, BCCP, FACC, FCCP, Kelsey E. Norman, PharmD, BCCP, BCACP, BCPS

Clinical insights on how real-world treatment persistence and discontinuation rates compare between the various non-statin therapies and the factors that contribute to these differences.

Episodes in this series

EP. 1 How Often Do Patients with ASCVD Achieve Target LDL-C?

EP. 1 How Often Do Patients with ASCVD Achieve Target LDL-C?

EP. 2 Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

EP. 2 Gaps Between Guidelines and Clinical Practice Patterns in ASCVD

A panel of 5 experts on ASCVD

EP. 3 Comparing the ACC/AHA and ESC/EAS Cholesterol Management Guidelines

A panel of 5 experts on ASCVD

EP. 4 Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

A panel of 5 experts on ASCVD

EP. 5 Evaluating Non-Statin Lipid-Lowering Therapies in ASCVD

A panel of 5 experts on ASCVD

EP. 6 Clinical Efficacy of Non-Statin Treatment Options in ASCVD

A panel of 5 experts on ASCVD

EP. 7 Non-Statin Therapies: Cost Effectiveness and Clinical Evidence Gaps

A panel of 5 experts on ASCVD

EP. 8 Persistence and Discontinuation Rates for Non-Statin Therapies in ASCVD

Video 9 - "The Role of Pharmacists in Treating Very High-Risk ASCVD"

EP. 9 The Role of Pharmacists in Treating Very High-Risk ASCVD

Video 10 - "Valuable Metrics and Improving Adherence in Patients With ASCVD"

EP. 10 Valuable Metrics and Improving Adherence in Patients With ASCVD

A panel of 5 experts on ASCVD

EP. 11 Successful Collaborative Care Strategies for Pharmacists

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Content

Business woman having headache at office

Stress Signals Drive Cardiovascular Disease Risk in Patients With Depression, Anxiety

ByLuke Halpern, Assistant Editor

December 25th 2025

A dedicated medical professional intently studies cardiomyopathy using a detailed heart model and notes

Aficamten Receives FDA Approval for Obstructive Hypertrophic Cardiomyopathy

ByLuke Halpern, Assistant Editor

December 22nd 2025

From Diagnosis to Transplant: A Heart Failure Patient’s Journey and the Pharmacists’ Impact Along the Way

ByCraig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Aislinn Antrim, Managing Editor

December 16th 2025

Woman holding hand on chest and having panic attack

Etripamil Becomes First, Only Self-Administered Nasal Spray Approved for PSVT

ByLuke Halpern, Assistant Editor

December 15th 2025

Skull image fusion with MRI MRA Brain for evaluate them stenosis and stroke disease.

Asundexian Reduces Risk of Future Ischemic Stroke as Secondary Prevention

ByLuke Halpern, Assistant Editor

December 10th 2025

Trending on Pharmacy Times

December 2025 Product Updates

Interview with Sa'ed al-Olimat, PharmD: How Pharmacists are Shaping the Future of Psychedelic Therapy

A Healthy Gut Could Improve Mental Health

Reimagining Pharmacy: A Call to Action for Pharmacy Professionals

FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia